Last updated: October 15, 2026
Neomycin and polymyxin B sulfates and hydrocortisone is a mature, low-cost anti-infective corticosteroid combination sold mainly in otic, ophthalmic and topical dosage forms. Its U.S. patent and regulatory exclusivity has expired, allowing multiple generic suppliers. Commercial value is concentrated in prescription volume, distributor availability, brand loyalty and manufacturing reliability rather than intellectual-property protection.
The product has no meaningful biosimilar risk because it is a conventional small-molecule and peptide-antibiotic combination, not a biologic. Public company filings do not provide a reliable standalone revenue figure for the combination. The financial trajectory is therefore best assessed through prescription demand, generic competition, branded niche pricing and supply continuity.
What is neomycin and polymyxin B with hydrocortisone used for?
The combination contains two antibiotics and a corticosteroid:
| Component |
Function |
| Neomycin sulfate |
Aminoglycoside antibiotic active against susceptible gram-positive and gram-negative organisms |
| Polymyxin B sulfate |
Antibiotic with activity primarily against susceptible gram-negative organisms |
| Hydrocortisone |
Low-potency corticosteroid that reduces inflammation, redness and itching |
The principal prescription applications are bacterial otitis externa, infected or inflamed external ear conditions, and selected ophthalmic infections or inflammatory conditions where the causative organism is susceptible and the clinician considers a steroid appropriate. Product labeling limits use in situations where fungal, viral or untreated systemic infections are present. Neomycin hypersensitivity and aminoglycoside-related ototoxicity are material clinical considerations, particularly when the tympanic membrane is perforated. (U.S. Food and Drug Administration [FDA], 2023a; National Library of Medicine [NLM], 2024a)
Common dosage forms include:
- Otic solution
- Otic suspension
- Ophthalmic suspension
- Ophthalmic ointment
- Topical ointment or cream
Concentrations vary by dosage form and manufacturer. A typical otic or ophthalmic liquid contains approximately 3.5 mg/mL neomycin base equivalent, 10,000 units/mL polymyxin B and 10 mg/mL hydrocortisone. Topical ointments generally use corresponding per-gram concentrations.
What brands and generic products compete with the combination?
Cortisporin is the principal historical brand associated with the combination. Generic products are marketed under descriptions such as neomycin and polymyxin B sulfates and hydrocortisone otic solution, otic suspension, ophthalmic suspension or ointment.
Competition differs by route of administration.
| Market segment |
Main competitors |
Competitive issue |
| Otic |
Ofloxacin, ciprofloxacin, ciprofloxacin/dexamethasone, acetic acid/hydrocortisone, neomycin/polymyxin B without steroid |
Fluoroquinolones may be preferred where tympanic membrane perforation or broader tolerability is a concern |
| Ophthalmic |
Tobramycin/dexamethasone, neomycin/polymyxin B/dexamethasone, polymyxin B/trimethoprim, ofloxacin and other antibiotic-steroid products |
Prescriber choice depends on diagnosis, steroid potency and ocular safety |
| Topical skin |
Neomycin/polymyxin B ointments, bacitracin combinations, mupirocin and topical corticosteroid-antibiotic products |
Allergy, antimicrobial stewardship and availability affect use |
Cortisporin and its generic equivalents retain demand because they are familiar, inexpensive and available in multiple dosage forms. The combination faces clinical substitution from fluoroquinolone otic products and from antibiotic-only products when inflammation is limited.
What is the FDA regulatory status of neomycin and polymyxin B with hydrocortisone?
The combination is an FDA-approved prescription product in several formulations. Generic versions generally rely on abbreviated new drug applications under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Approval requires pharmaceutical equivalence and bioequivalence or other applicable equivalence evidence to the reference product. (FDA, 2024a)
The regulatory position is fragmented by dosage form. Approval of an otic solution does not automatically establish substitutability for an otic suspension, ophthalmic suspension or ointment. Pharmacy substitution depends on the specific FDA-approved product and therapeutic-equivalence designation.
What is the Orange Book status?
The FDA Orange Book identifies reference-listed drugs and approved generic equivalents by dosage form and strength. The relevant products are generally listed as mature reference products with multiple abbreviated new drug application approvals. The current commercial significance is therefore tied to therapeutic-equivalence ratings, supply and formulary placement rather than patent exclusivity. (FDA, 2024b)
The Orange Book does not create a continuing market monopoly for the active ingredients. Any remaining listed patent information must be reviewed at the product and dosage-form level, but the historic combination has no widely recognized active U.S. patent barrier comparable to newer branded medicines.
What patents protect neomycin and polymyxin B with hydrocortisone?
No meaningful active U.S. composition-of-matter patent estate protects the underlying combination. The active ingredients and the basic combination are decades old. Any original U.S. patents associated with the product class would have expired long ago under both historical patent terms and modern 20-year-from-filing calculations.
| IP category |
Current commercial position |
| Active-ingredient patents |
Expired |
| Basic combination patents |
Expired or no longer commercially relevant |
| Formulation patents |
No broadly recognized active U.S. formulation barrier for the standard products |
| Method-of-use patents |
No material exclusivity identified for routine otic, ophthalmic or topical use |
| Manufacturing patents |
Process know-how may remain proprietary, but it does not block generic entry |
| Trademark rights |
Brand names such as Cortisporin may remain protected, but trademarks do not prevent generic substitution |
Patent protection can still arise around a particular device, preservative system, container, suspension technology or manufacturing process. Such rights would be narrower than protection for the active ingredients and would not ordinarily prevent approval of a conventional competing product.
When does neomycin and polymyxin B with hydrocortisone lose exclusivity?
The product lost meaningful exclusivity many years ago. There is no upcoming loss-of-exclusivity event comparable to a modern branded drug facing its first generic entry.
The relevant timeline is:
| Event |
Timing |
| Initial development and commercialization |
Mid-20th century era |
| Original brand protection |
Expired decades ago |
| Generic approvals |
Established for multiple dosage forms |
| Current status |
Mature multisource generic market |
| Future exclusivity event |
None identified |
Because the market is already genericized, revenue erosion occurs through continuing price pressure, pharmacy substitution and supplier competition rather than through a single patent cliff.
Are there Paragraph IV challenges or generic litigation?
Paragraph IV litigation is not a material current risk driver for the standard combination. A Paragraph IV certification is relevant when an ANDA applicant challenges an unexpired Orange Book-listed patent. The core product has no known active patent barrier that would support a conventional first-entry patent dispute.
Generic applicants may still use Paragraph III, Paragraph IV or other certifications depending on the reference product’s listed patents and regulatory status. For this old combination, the practical entry question is usually approval and manufacturing readiness, not litigation over patent validity.
No major recent U.S. patent litigation involving the standard neomycin, polymyxin B and hydrocortisone combination is broadly identified in public regulatory and company disclosures. Product-liability, labeling and quality disputes remain legally distinct from patent litigation.
Are there settlement agreements affecting generic entry?
No publicly material patent-settlement agreement is associated with a current U.S. exclusivity barrier for the basic combination. Generic entry is generally open to any manufacturer that can satisfy FDA chemistry, manufacturing, controls and equivalence requirements.
How strong is the patent estate?
The patent estate is weak for market-exclusion purposes and moderate only in the limited sense that manufacturing know-how and trademarks can protect individual suppliers.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
None of practical value |
| Remaining patent life |
No material standard-product protection |
| Formulation barriers |
Narrow and product-specific |
| Method-of-use protection |
Weak or absent |
| Generic design-around difficulty |
Low to moderate |
| Litigation leverage |
Low |
| Trademark differentiation |
Moderate for established brands |
| Supply-chain differentiation |
Moderate |
The greatest barriers are operational. Sterile manufacturing, preservative control, microbiological quality, suspension uniformity, container compatibility and reliable supply of polymyxin B and neomycin can limit the number of consistent suppliers. Those barriers may support pricing above commodity levels without creating legal exclusivity.
What is the financial trajectory for the product?
The financial trajectory is mature and defensive rather than growth-oriented.
Public filings from companies associated with the product do not consistently disclose standalone revenue for each neomycin, polymyxin B and hydrocortisone SKU. As a result, precise product-level revenue, gross margin and market-share estimates cannot be derived from public company reporting. The commercial profile is nevertheless clear:
- Unit prices are constrained by generic competition.
- Demand is recurring but tied to episodic ear, eye and skin infections.
- Brand products can command a premium when prescribers or pharmacies prefer a recognized supplier.
- Short treatment courses limit prescription duration and refill frequency.
- Supply disruptions can temporarily improve pricing for manufacturers with inventory.
- Long-term volume growth is likely to track diagnosis rates, prescribing patterns and population demographics rather than innovation.
The branded opportunity is strongest where a manufacturer has an established sales channel, reliable sterile production and contracts with wholesalers, hospitals or managed-care organizations. The generic opportunity is more volume-driven and depends on manufacturing cost, product availability and purchasing contracts.
What revenue exposure do manufacturers have?
For a diversified pharmaceutical company, the combination is unlikely to be a major revenue driver unless the company has a concentrated portfolio of mature ophthalmic and otic products. Revenue exposure typically falls into one of three categories:
| Manufacturer position |
Financial exposure |
| Brand owner |
Higher unit price, lower volume, vulnerability to generic substitution |
| Authorized generic supplier |
Lower price, potentially stable volume |
| Commodity generic manufacturer |
Low margin, sensitive to tenders and supply interruptions |
| Specialty distributor or contract manufacturer |
Revenue linked to channel access and production capacity |
ANI Pharmaceuticals, which markets multiple established prescription products, has reported portfolio-level financial information rather than a consistently separated public revenue line for every Cortisporin-related product. (ANI Pharmaceuticals, Inc., 2024) This limits direct valuation of the combination from public filings.
What manufacturing and intellectual-property barriers affect supply?
The combination is legally easy to enter but technically less trivial to manufacture than a simple tablet.
Key manufacturing requirements include:
- Sterile liquid or semisolid production
- Control of microbial contamination
- Accurate potency measurement for neomycin and polymyxin B
- Suspension particle-size and uniformity control
- Preservative effectiveness, where applicable
- Container and closure compatibility
- Stability under storage and transport conditions
- Ongoing FDA compliance for sterile facilities
Polymyxin B is a complex mixture of related components rather than a single conventional small molecule. That creates analytical and potency-control requirements. The issue is a manufacturing and quality barrier, not a patent barrier.
What geographic coverage does the product have?
The combination is marketed internationally under different brand names, generic names and regulatory classifications. Patent protection is not globally uniform, but the age of the active ingredients means the principal markets are generally post-exclusivity.
Commercial differences by region include:
- United States: FDA-approved prescription products with multiple generic suppliers
- European Union: national or decentralized authorization structures, with established generic competition
- Canada and Australia: mature prescription markets with generic substitution
- Emerging markets: broader variation in prescription, pharmacy and over-the-counter access
Geographic revenue depends more on registration status, local pricing controls, tender access and distributor reach than on patent enforcement.
What generic launch scenarios exist?
The most likely launch scenarios are operational rather than litigation-driven.
| Scenario |
Market effect |
| New ANDA approval with several existing suppliers |
Limited price and share impact |
| Supplier exit or manufacturing disruption |
Temporary volume and pricing opportunity |
| Brand relaunch with improved packaging or channel access |
Modest premium potential |
| New preservative-free or device-based formulation |
Possible niche differentiation |
| Hospital or public tender win |
Volume growth with margin pressure |
| Safety concern involving aminoglycoside use |
Substitution toward fluoroquinolone products |
A new entrant would need a competitive cost structure, dependable sterile capacity and wholesaler access. Patent clearance would generally be straightforward for a conventional formulation.
How does the product compare with newer antibiotic-steroid combinations?
Neomycin/polymyxin B/hydrocortisone has a cost advantage and broad historical familiarity. Fluoroquinolone-steroid products have stronger commercial positioning in situations involving concern about aminoglycoside allergy, ototoxicity or tympanic membrane perforation, but they are usually more expensive.
| Attribute |
Neomycin/polymyxin B/hydrocortisone |
Fluoroquinolone-steroid products |
| Patent position |
Expired, generic |
Some products had later protection, but many are now generic |
| Cost |
Low |
Generally higher |
| Prescriber familiarity |
High |
High in otic practice |
| Ototoxicity concern |
Relevant |
Generally lower concern for approved otic use |
| Differentiation |
Limited |
Device, dosing and safety positioning |
| Growth outlook |
Stable to declining |
More resilient in selected indications |
Key Takeaways
- Neomycin and polymyxin B sulfates with hydrocortisone is a mature generic combination with no meaningful active composition patent protection.
- Cortisporin remains the best-known brand association, while generic products dominate unit supply.
- The main dosage forms are otic solution, otic suspension, ophthalmic suspension and ointment.
- FDA regulatory status is established, with generic approval through ANDA pathways.
- Paragraph IV litigation and patent settlements are not material current market factors.
- Biosimilar risk is not applicable because the product is not a biologic.
- Commercial value depends on sterile manufacturing, supply reliability, channel access and formulary positioning.
- Product-level revenue is generally not separately disclosed by public companies.
- Competitive pressure comes mainly from fluoroquinolone otic products, antibiotic-only products and other antibiotic-steroid combinations.
- The financial trajectory is stable-to-declining in price, with episodic opportunities during supplier shortages or manufacturing disruptions.
FAQs
Is neomycin, polymyxin B and hydrocortisone still under patent?
No material patent protection remains for the standard active-ingredient combination in the United States. Narrow patents could exist for a specific formulation, container or manufacturing process, but they do not generally block conventional generic entry.
Is Cortisporin the same as neomycin and polymyxin B with hydrocortisone?
Cortisporin is a brand associated with formulations containing neomycin, polymyxin B and hydrocortisone. The exact dosage form and concentration must be checked because otic, ophthalmic and topical products are not automatically interchangeable.
Can pharmacies substitute generic neomycin and polymyxin B with hydrocortisone?
Substitution depends on the FDA therapeutic-equivalence designation and the specific dosage form. An otic generic cannot automatically be substituted for an ophthalmic product, and an ophthalmic suspension cannot automatically be substituted for an ointment.
Does neomycin and polymyxin B with hydrocortisone have biosimilar competition?
No. Biosimilar regulation applies to biological products. This combination is regulated as a conventional drug product, with generic competition handled through abbreviated applications.
What is the main investment risk for manufacturers of this combination?
The main risks are price erosion, sterile manufacturing problems, product recalls, supplier concentration and substitution by fluoroquinolone-based products. Patent expiration is not the principal risk because the market is already post-exclusivity.
References
ANI Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
National Library of Medicine. (2024a). DailyMed: Neomycin and polymyxin B sulfates and hydrocortisone otic solution. U.S. National Library of Medicine.
National Library of Medicine. (2024b). DailyMed: Neomycin and polymyxin B sulfates and hydrocortisone ophthalmic suspension. U.S. National Library of Medicine.
U.S. Food and Drug Administration. (2023a). Cortisporin otic solution: Prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024a). Abbreviated new drug application process. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Department of Health and Human Services.
